STABILITY – what went wrong for GSK's darapladib?
This article was originally published in Scrip
Executive Summary
The full results from GlaxoSmithKline's failed Phase III STABILITY study of its Lp-PLA2 inhibitor darapladib presented this weekend at the American College of Cardiology meeting in Washington DC shed further light on its clinical profile. While the investigational drug's prospects are not good, the data show that it did at least produce some statistical benefits on some secondary endpoints, leaving some experts with a glimmer of hope that it may prove useful in certain patient subgroups.